At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 18, 2026 at 16:10 ET
Reviva Pharmaceuticals (RVPH) announced plans for a public offering of common stock and warrants, with proceeds intended to fund its Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia and general corporate purposes. The offering size, pricing, and terms have not been disclosed, and completion is subject to market conditions.
- Reviva Pharmaceuticals is conducting a public offering of common stock (or equivalents) and warrants.
- All securities are being offered by the company; no selling shareholders mentioned.
- A.G.P./Alliance Global Partners is the sole placement agent.
- Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine, R&D, and general corporate purposes.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access